A high-activity UK & EU sector, led by NHS ENGLAND, most recent listing 12 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
This announcement is for establishing agreements with pharmaceutical companies as per § 130a Abs. 8 Sentence 1 SGB V. The invitation to participate is directed only to pharmaceutical entrepreneurs or associations of pharmaceutical entrepreneurs as defined in § 4 Abs. 18 of the Medicines Act. This is
This announcement is for establishing agreements with companies or consortia of companies for blood glucose test strips in accordance with § 130a Abs. 8 Satz 1 of the Fifth Book of the Social Code (SGBV) for the state of North Rhine-Westphalia. The agreements will include discount contracts, allowin
This contract opportunity involves the establishment of non-exclusive discount contracts for medications containing the active ingredients Olodaterol and Tiotropium Bromide. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the possibility of entering into contracts a
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Tramadol and Paracetamol, in accordance with German social law. The contracts will be valid from October 1, 2025, to September 30, 2027, and suppliers can enter into contracts at
The Kaufmännische Krankenkasse (KKH) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under Section 130a, Paragraph 8 of the Social Code Book V (SGB V) through an 'Open-House' procedure. This process allows all eligible and interes
The health insurance funds (whether HEK and/or hkk participate in each lot is determined by the designation of the respective lot) aim to establish discount contracts with all suitable pharmaceutical companies according to § 130a Abs. 8 SGB V for the active ingredients, combinations of active ingred
The KKH (Kaufmännische Krankenkasse) is seeking to establish non-exclusive discount agreements with pharmaceutical companies for specific active ingredients under the Open-House procedure. This opportunity is open to all qualified pharmaceutical companies or groups of companies interested in enterin
This contract opportunity involves establishing a non-exclusive discount agreement for the medication Omalizumab (ATC Code: R03DX05) in Germany. The contract will be effective from December 1, 2024, to November 30, 2026, with the option for suppliers to enter into the contract at any time during thi
The DAK-Gesundheit is seeking pharmaceutical companies to enter into a non-exclusive discount agreement for the drug Umeclidinium (ATC R03BB07) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will follow the formal
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Abrocitinib (ATC D11AH08) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from September 1, 2025, to August 31, 2027. The process will involve formal procurement proced
